CARDAMYST Launch Gains Traction: 50% Commercial Coverage, Phase 3 AFib Trial Opens
MIST is trading near its 52-week low of $1 (13% above the low).
Summary
Milestone's Q2 update shows CARDAMYST launch momentum: over 800 prescribers and 1,500 scripts filled, with commercial coverage recently jumping to over 50% of lives. The Phase 3 ReVeRA-301 trial in AFib-RVR is now open and enrolling, targeting a larger adjacent indication. Cash of $170.6M provides runway into H2 2027. The EMA decision on PSVT in Europe is expected in H1 2027, and the NMPA review in China is ongoing. This follows the 10-Q filed today, adding management commentary and specific launch metrics that confirm accelerating adoption.
At the time of this announcement, MIST was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.1M. The 52-week trading range was $1.00 to $3.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.